trending Market Intelligence /marketintelligence/en/news-insights/trending/BKyylnwywGL2kUcRxAeh_Q2 content esgSubNav
In This List

Acorda's Parkinson's treatment Inbrija wins marketing approval in Europe

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Acorda's Parkinson's treatment Inbrija wins marketing approval in Europe

Ardsley, N.Y.-based Acorda Therapeutics Inc.'s Inbrija was granted marketing authorization by the European Commission to treat certain Parkinson's disease patients.

Inbrija is a formulation of levodopa, one of the main drugs used to treat certain symptoms of Parkinson's disease.

The drug is used for adult patients experiencing so-called off periods, when the effects of an existing medication start to wear off in between doses, or the symptoms of Parkinson's reemerge.

Previously, the U.S. Food and Drug Administration approved Inbrija for the intermittent treatment of off periods in people with Parkinson's treated with carbidopa or levodopa.